Who We Are
We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx(tm) protein expression system. Using our ProCellEx(tm) system we are developing a pipeline of proprietary recombinant therapeutic proteins based on our plant cell-based expression technology that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action.

Our initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe our ProCellEx(tm) protein expression system will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant proteins currently marketed for the same indications. In addition, we believe our ProCellEx protein expression system will enable us to express and produce bio similar or "generic" versions of other recombinant proteins not protected through patents in a cost effective manner.

Because we are targeting primarily biologically equivalent versions ("Biosimilar versions") of highly active, well-tolerated and commercially successful therapeutic proteins, we believe our development process is associated with relatively less risk compared to other biopharmaceutical development processes for novel therapeutic proteins. (Information from www.protalix.com).

Contact information:
Protalix Biotherapeutics
2 Snunit St., Science Park,
POB 455, Carmiel 20100, Israel.
T: +972-4-902-8100
F: +972-4-988-9489
Toll Free: +972-1800-200-244
E: patient-info@protalix.com
Website: www.protalix.com
Patient website:
http://www.protalix.com/Patients/ProtalixPatientsCare.html